INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Option exerciseVerified data

Roberts M Scot reported ALT

Chief Scientific Officer · Altimmune, Inc. · Common Stock, par value $0.0001

Side
M
Value
—
Shares
14.6K
Price
—
Executed
Jan 25, 2026
Disclosed
Jan 27, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 25 executedJan 27, 2026 disclosed

ALT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+5 / 25

No reported dollar value · 19.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ALT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    HG
    Howarth Alex G.Director
    ALTAltimmune, Inc.
    Grant or award
    		A—
    160.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GP
    Greenleaf PeterDirector
    ALTAltimmune, Inc.
    Grant or award
    		A—
    160.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MT
    Menziuso Richard ThomasPrincipal Accounting Officer
    ALTAltimmune, Inc.
    Grant or award
    		A—
    36.2K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MT
    Menziuso Richard ThomasPrincipal Accounting Officer
    ALTAltimmune, Inc.
    Grant or award
    		A—
    84.5K sh
    		Oct 1, 2026Oct 2, 2026
    traded Oct 1, 2026
    		+1dSEC FORM 4

    Evidence

    33
    DB
    Durso Jerome BenedictDirector, President and CEO
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$44K
    15.0K sh
    		Aug 13, 2026Aug 13, 2026
    traded Aug 13, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LL
    Lawver Teri LDirector
    ALTAltimmune, Inc.
    Grant or award
    		A—
    48.8K sh
    		May 1, 2026May 1, 2026
    traded May 1, 2026
    		+0dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Grant or award
    		A$14K
    4,571 sh
    		Jan 31, 2026Feb 2, 2026
    traded Jan 31, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$29K
    4,748 sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    21
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$26K
    4,229 sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    15.8K sh
    		Jan 27, 2026Jan 29, 2026
    traded Jan 27, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$24K
    4,373 sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    RS
    Roberts M ScotChief Scientific Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    13
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Tax withholding
    		F$21K
    3,855 sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    21
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    17
    JM
    Jordt Raymond MChief Business Officer
    ALTAltimmune, Inc.
    Option exercise
    		M—
    14.6K sh
    		Jan 25, 2026Jan 27, 2026
    traded Jan 25, 2026
    		+2dSEC FORM 4

    Evidence

    41
    PW
    Pisano WayneDirector
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$20K
    5,000 sh
    		Jan 8, 2026Jan 9, 2026
    traded Jan 8, 2026
    		+1dSEC FORM 4

    Evidence

    44
    DB
    Durso Jerome BenedictDirector
    ALTAltimmune, Inc.
    Open-market purchase
    		BUY$52K
    12.5K sh
    		Dec 22, 2025Dec 22, 2025
    traded Dec 22, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001705905-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 25, 2026
    Published
    Jan 27, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Roberts M Scot
    Role
    Chief Scientific Officer
    Transaction
    Option exerciseAs filed: “M”
    Asset
    Altimmune, Inc.
    Ticker
    ALT
    Shares
    14.6K
    Price per share
    $0
    Execution date (reported)
    Jan 25, 2026
    Owned after transaction
    88.7K shares
    Days from execution to publication
    2

    What this establishes

    Roberts M Scot filed this Form 4 reporting a option exercise of ALT on Jan 25, 2026. It became public on Jan 27, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Roberts M Scotcik:0001705905
    Issuer
    Altimmune, Inc.cik:0001326190

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.